Last 29 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -10.16 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 5.94 | 4.68 | 5.39 | 4.49 | 3.66 | 10.32 | 9.30 | 7.08 | 7.60 | 8.96 | 20.00 | 8.26 | 5.55 |
| — | -54.7% | -42.1% | -36.6% | -51.8% | +15.2% | -53.5% | -14.2% | +37.1% | +62.9% | +1116.5% | +692.7% | +306.5% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -62.5% | -14.7% | -22.4% | -18.3% | -20.1% | -27.7% | -22.0% | -15.0% | -11.6% | -11.0% | -21.3% | -22.3% | -15.3% |
| — | +47.0% | -2.1% | -22.2% | -72.9% | -151.0% | -3.3% | +32.8% | +24.1% | +29.2% | -84.6% | -150.6% | -58.1% | |
| ROA | -57.4% | -13.5% | -20.3% | -16.8% | -17.8% | -23.7% | -19.7% | -13.9% | -10.9% | -10.2% | -18.2% | -19.5% | -13.8% |
| — | +43.0% | -3.0% | -20.9% | -62.7% | -131.5% | -8.3% | +29.0% | +20.7% | +28.3% | -68.7% | -135.7% | -54.7% | |
| ROIC | — | — | -2648.3% | -5959.9% | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 160.7% YoY to 15.74x, strengthening the short-term liquidity position.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | — | — | — | -37.7% | -85.6% | -95.7% | -95.9% | -93.4% | -87.7% | -46.4% | -35.8% | -33.1% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 11.16 | 15.74 | 9.07 | 12.32 | 11.16 | 6.04 | 7.61 | 13.08 | 13.70 | 22.14 | 7.23 | 6.82 | 9.34 |
| — | +160.7% | +19.1% | -5.8% | -18.5% | -72.7% | +5.2% | +92.0% | +46.7% | +101.0% | -46.0% | -68.3% | -18.9% | |
| Quick Ratio | 11.16 | 15.74 | 9.07 | 12.32 | 11.16 | 6.04 | 7.61 | 13.08 | 13.70 | 22.14 | 7.23 | 6.82 | 9.34 |
| — | +160.7% | +19.1% | -5.8% | -18.5% | -72.7% | +5.2% | +92.0% | +46.7% | +101.0% | -46.0% | -68.3% | -18.9% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 29 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonImmunovant, Inc.'s current P/E is -10.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Immunovant, Inc.'s business trajectory between earnings reports.